Genmab A/SGMABNASDAQ
Loading
Cash Flow PerformanceStrong
Percentile Rank93
3Y CAGR+26.8%
5Y CAGR+3.7%
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

3Y CAGR
+26.8%/yr
vs +60.8%/yr prior
5Y CAGR
+3.7%/yr
Recent acceleration
Acceleration
-34.0pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$7.33B-3.4%
2024$7.58B+8.3%
2023$7.00B+94.8%
2022$3.60B+81.9%
2021$1.98B-67.7%
2020$6.13B+404.2%
2019$1.22B+126.1%
2018$537.42M-64.2%
2017$1.50B+409.3%
2016$294.61M-